360 related articles for article (PubMed ID: 15667232)
1. Clinical monograph for drug formulary review: systemic agents for psoriasis/psoriatic arthritis.
Fisher VS
J Manag Care Pharm; 2005; 11(1):33-55. PubMed ID: 15667232
[TBL] [Abstract][Full Text] [Related]
2. Clinical monograph for drug formulary review: erectile dysfunction agents.
Campbell HE
J Manag Care Pharm; 2005 Mar; 11(2):151-71. PubMed ID: 15766322
[TBL] [Abstract][Full Text] [Related]
3. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
Weinberg JM
Clin Ther; 2003 Oct; 25(10):2487-505. PubMed ID: 14667953
[TBL] [Abstract][Full Text] [Related]
4. Advancements in the treatment of psoriasis: role of biologic agents.
Rich SJ; Bello-Quintero CE
J Manag Care Pharm; 2004; 10(4):318-25. PubMed ID: 15298530
[TBL] [Abstract][Full Text] [Related]
5. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
[TBL] [Abstract][Full Text] [Related]
6. Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis.
Schafer JA; Kjesbo NK; Gleason PP
J Manag Care Pharm; 2010; 16(6):402-16. PubMed ID: 20635831
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
Brimhall AK; King LN; Licciardone JC; Jacobe H; Menter A
Br J Dermatol; 2008 Aug; 159(2):274-85. PubMed ID: 18547300
[TBL] [Abstract][Full Text] [Related]
8. Psoriatic arthritis therapy advances.
Mease PJ
Curr Opin Rheumatol; 2005 Jul; 17(4):426-32. PubMed ID: 15956839
[TBL] [Abstract][Full Text] [Related]
9. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
Woolacott N; Bravo Vergel Y; Hawkins N; Kainth A; Khadjesari Z; Misso K; Light K; Asseburg C; Palmer S; Claxton K; Bruce I; Sculpher M; Riemsma R
Health Technol Assess; 2006 Sep; 10(31):iii-iv, xiii-xvi, 1-239. PubMed ID: 16948890
[TBL] [Abstract][Full Text] [Related]
10. Biologic Therapy Utilization in Patients With Moderate to Severe Psoriasis and Psoriatic Arthritis: An Observational Summary of Biologic Therapy Use in a Clinical Setting.
Gulliver WP; Randell S; Gulliver S; Gregory V; Nagle S; Chambenoit O
J Cutan Med Surg; 2018; 22(6):567-576. PubMed ID: 29952225
[TBL] [Abstract][Full Text] [Related]
11. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ
J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
[TBL] [Abstract][Full Text] [Related]
12. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
Rodgers M; Epstein D; Bojke L; Yang H; Craig D; Fonseca T; Myers L; Bruce I; Chalmers R; Bujkiewicz S; Lai M; Cooper N; Abrams K; Spiegelhalter D; Sutton A; Sculpher M; Woolacott N
Health Technol Assess; 2011 Feb; 15(10):i-xxi, 1-329. PubMed ID: 21333232
[TBL] [Abstract][Full Text] [Related]
13. Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies.
Elyoussfi S; Thomas BJ; Ciurtin C
Rheumatol Int; 2016 May; 36(5):603-12. PubMed ID: 26892034
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A; Esposito M; Costanzo A; Chimenti S
Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
[TBL] [Abstract][Full Text] [Related]
15. An evidence-based review of the mechanism of action, efficacy, and safety of biologic therapies in the treatment of psoriasis and psoriatic arthritis.
Brezinski EA; Armstrong AW
Curr Med Chem; 2015; 22(16):1930-42. PubMed ID: 25921645
[TBL] [Abstract][Full Text] [Related]
16. Treatments for psoriasis and the risk of malignancy.
Patel RV; Clark LN; Lebwohl M; Weinberg JM
J Am Acad Dermatol; 2009 Jun; 60(6):1001-17. PubMed ID: 19344980
[TBL] [Abstract][Full Text] [Related]
17. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L
Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302
[TBL] [Abstract][Full Text] [Related]
18. AMCP Format dossier requests: manufacturer response and formulary implications for one large health plan.
Spooner JJ; Gandhi PK; Connelly SB
J Manag Care Pharm; 2007; 13(1):37-43. PubMed ID: 17269835
[TBL] [Abstract][Full Text] [Related]
19. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Guelimi R; Garcia-Doval I; Hua C; Hughes C; Naldi L; Kinberger M; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2023 Jul; 7(7):CD011535. PubMed ID: 37436070
[TBL] [Abstract][Full Text] [Related]
20. Biologics in the management of psoriasis.
Bahner JD; Cao LY; Korman NJ
Clin Cosmet Investig Dermatol; 2009 Jul; 2():111-28. PubMed ID: 21436974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
